Steady-state pharmacokinetics of indobufen enantiomers in patients with obliterative atherosclerosis

Chirality

Volumn 13, Issue 6, 2001, Pages 308-312

  GLowka F K ^a   Strzelecka, D ^a   Zapalski, S ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Bleeding time; Chiral Pharmacokinetics; Indobufen enantiomers; Obliterative atherosclerosis

Indexed keywords

INDOBUFEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG HALF LIFE; ENANTIOMER; FEMALE; HUMAN; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STEADY STATE; TABLET; ULTRAVIOLET RADIATION;

AGED; AREA UNDER CURVE; ARTERIOSCLEROSIS OBLITERANS; BLEEDING TIME; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYLBUTYRATES; PLATELET AGGREGATION INHIBITORS; STEREOISOMERISM;

EID: 0034984124     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.1036     Document Type: Article

References (13)

1. Crow MJ, Salter MCP, Donaldson DR. Rajah SM. Inhibition of platelet function with indobufen: correlation with plasma drug level. Thrornb Res 1985;38:303-306.
2. Patrignani P, Volpi D, Ferrario R, Romanzini L, Di Somma M, Patrono C. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipooxygenase activities in human whole blood. Eur J Pharmacol 1990; 191:83-88.
3. Cerletti C, Manarini S, Colombo M, Tavani A. The (+)-enantiomer is responsible for the antiplatelet and antiinflammatory activity of (±)-indobufen. J Pharm Pharmacol 1990;42:885-887.
4. De Caterina R, Sicari R, Yan A, Bernini W, Giannessi D, Lazzerini G, Efthymiopoulos C, Strolin-Benedetti M. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man. Thromb Haemostas 1992;67:258-263.
5. Strolin-Benedetti M, Frigerio E, Tamassia V, Noseda G, Caldwell J. The dispositional enantioselectivity of indobufen in man. Biochem Pharmacol 1992;43:2032-2034.
6. Główka FK. Stereoselective pharmacokinetics of indobufen from tablets and intramuscular injections in man. Chirality 2000;12:38-42.
7. Fuccella LM, Corvi G, Moro E, Pogliani E, Tamassia V, Tosolini G. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man. Eur J Clin Pharmacol 1979;15:323-327.
8. Li G, Treiber G, Maier K, Walker S, Klotz U. Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. Clin Phrmacokinet 1993;25:154-163.
9. Dmoszyńska A, Janicki K, Janicka L, Przesmycki K, Sokolowska B, Walter-Croneck A. Influence of indobufen on occlusion of arteriovenous fistulas and some platelet activity in intermittent peritoneal dialysis patients. Pol J Pharmacol 1996;48:327-329.
10. Główka FK. LC procedure with SPE for quantification of indobufen enantiomers: pharmacokinetics studies. J Pharm Biomed Anal 2000; 22:93-100.
11. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982. p 113-144.
12. Heinzel G, Woloszczak R, Thomann P. Topfit 2.0. Pharmacokinetic and pharmacodynamic data analysis system for the PC. New York: Gustav Fischer; 1993.
13. Hutt AI, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids - a novel route with pharmacological consequences. J Pharm Pharmacol 1983;35:693-704.